Veracyte Breakfast Symposium – The New Afirma Genomic Sequencing Classifier – Leveraging Enriched Genomic Data through RNA Sequencing and Advancements in Machine Learning to Identify More Benign Thyroid Nodules

      The New Afirma Genomic Sequencing Classifier – Leveraging Enriched Genomic Data through RNA Sequencing and Advancements in Machine Learning to Identify More Benign Thyroid Nodules Date: Sunday, July 30th Time: 6:00 am – 7:30 am Location: Marina Ballroom Speakers:
    • Giulia C. Kennedy, Chief Scientific Officer and Senior Vice President of Research and Development, Veracyte
    • Richard T. Kloos, Senior Medical Director, Endocrinology, Veracyte
    • Plus, an expert clinician guest speaker
    This special presentation will provide an in-depth overview of Veracyte’s next-generation Afirma Genomic Sequencing Classifier (GSC). The event will cover the following learning objectives:
    • Discuss scientific development of the Afirma GSC
    • Review Afirma GSC validation results
    • Illustrate impact of Afirma GSC’s improved test performance –  Increase benign results by >30% to further reduce unnecessary surgeries –  Increase prevalence of cancer in Afirma GSC Suspicious cases

 

Leave a Reply